OGDHL Antibody

What is OGDHL and why is it a significant target for antibody-based research?

OGDHL, also known as 2-oxoglutarate dehydrogenase-like protein, is an enzyme traditionally associated with the citric acid cycle and amino acid metabolism . It plays a crucial role in cellular energy production pathways and is essential for normal metabolic function. The significance of OGDHL extends beyond basic metabolism, as research has revealed its dysregulation in various diseases including cancer, metabolic disorders, and neurodegenerative conditions .

Understanding OGDHL function through antibody-based detection can provide valuable insights into these pathological conditions. The protein has a calculated molecular weight of approximately 114kDa but is typically observed at around 120kDa in experimental settings . OGDHL antibodies enable researchers to track expression patterns, localization changes, and protein-protein interactions that might reveal new therapeutic targets.

How should researchers select the appropriate OGDHL antibody for specific experimental applications?

Selection of an OGDHL antibody should be guided by your specific experimental requirements:

• Application compatibility: Verify the antibody has been validated for your intended application (WB, IHC, ELISA, ICC, IF) . For example, ABIN7269135 is validated for both Western Blotting and Immunohistochemistry .

• Species reactivity: Confirm reactivity with your experimental model. Some antibodies react with human samples only, while others show cross-reactivity with mouse, rat, dog, pig, or other species .

• Epitope recognition: Different antibodies target distinct regions of OGDHL. For studying specific domains, select antibodies targeting relevant regions (N-terminal, internal regions, etc.) .

• Clonality consideration: Polyclonal antibodies offer broader epitope recognition but may have batch variation, while monoclonal antibodies provide consistency and specificity .

• Format requirements: Consider whether you need unconjugated antibodies or conjugation-ready formats for specialized applications .

The following table summarizes key considerations for OGDHL antibody selection:

What are the optimal storage and handling procedures for maintaining OGDHL antibody activity?

Proper storage and handling of OGDHL antibodies are critical for maintaining their activity and specificity:

For lyophilized antibodies:

• Store at 4°C until reconstitution

• Reconstitute with distilled water to achieve the recommended concentration (typically 1 mg/mL in PBS buffer)

• Following reconstitution, aliquot to avoid repeated freeze-thaw cycles

• Store aliquots at -20°C for longer-term storage

For liquid antibodies:

• Store at -80°C for optimal stability

• Avoid repeated freeze-thaw cycles as this can degrade antibody performance

• Follow manufacturer-specific recommendations, as buffer compositions may vary

Working dilutions should be prepared fresh before use, particularly for sensitive applications. For Western blotting applications, typical working dilutions range from 1:200 to 1:2000, while IHC applications generally require 1:50 to 1:200 dilutions .

How can researchers validate the subcellular localization of OGDHL using antibody-based techniques?

Recent research has revealed that OGDHL, traditionally considered a mitochondrial matrix protein, also localizes to the nucleus - a finding with significant implications for understanding its non-canonical functions . To properly validate OGDHL subcellular localization:

• Immunofluorescence protocol optimization:

  • Use positive control samples known to express OGDHL (e.g., LO2 cells, mouse kidney, mouse brain, rat kidney)

  • Compare multiple antibodies targeting different epitopes to confirm specificity

  • Include appropriate subcellular markers for co-localization studies (mitochondrial and nuclear markers)

• Subcellular fractionation with Western blot:

  • Separate nuclear, mitochondrial, and cytosolic fractions

  • Use marker proteins for each fraction to verify separation quality

  • Probe for OGDHL in each fraction using validated antibodies

• Confirmation with tagged constructs:

  • Compare localization patterns of endogenous OGDHL (detected by antibodies) with tagged OGDHL constructs

  • Consider using the nuclear-deficient OGDHL/3KA mutant (560SKDKK564 sequence modified) as a control for nuclear localization specificity

Research has identified a specific nuclear localization sequence (NLS) in OGDHL (560SKDKK564) that can be experimentally manipulated to study the importance of nuclear localization for its function .

What role does OGDHL play in cancer progression and how can antibodies help elucidate its mechanisms?

Recent studies have revealed that OGDHL is downregulated in hepatocellular carcinoma (HCC) and plays a tumor-suppressive role through multiple mechanisms . OGDHL antibodies are essential tools for understanding these processes:

• Expression profiling in cancer tissues:

  • OGDHL antibodies can be used for immunohistochemistry to analyze expression patterns in tumor versus normal tissues

  • Downregulation of OGDHL has been observed in both human and mouse HCC

• Mechanism of action studies:

  • Nuclear OGDHL has been shown to induce DNA damage in HCC cells independently of its enzymatic activity

  • Antibodies that can distinguish between nuclear and mitochondrial OGDHL are valuable for mechanistic studies

• Protein-protein interaction analysis:

  • Co-immunoprecipitation with OGDHL antibodies has revealed its interaction with CDK4, inhibiting CDK4 phosphorylation by CAK and consequently suppressing E2F1 signaling

  • This mechanism leads to reduced nucleotide synthesis, dNTP depletion, and subsequent DNA damage in cancer cells

• Therapeutic target validation:

  • OGDHL antibodies can help validate its potential as a therapeutic target for HCC

  • Preliminary experiments suggest OGDHL may enhance antitumor immunity in HCC, requiring further exploration with antibody-based methods

How can researchers distinguish between the enzymatic and non-enzymatic functions of OGDHL?

OGDHL has both enzymatic functions related to the TCA cycle and newly discovered non-enzymatic functions, particularly in the nucleus. Discriminating between these activities requires specialized approaches:

• Domain-specific antibodies:

  • Antibodies targeting different domains can help distinguish functions associated with specific protein regions

  • N-terminal antibodies (AA 1-110) may reveal different localization or interaction patterns compared to antibodies targeting other regions

• Enzymatic activity assays coupled with immunoprecipitation:

  • Use OGDHL antibodies to immunoprecipitate the protein

  • Measure enzymatic activity in the precipitate

  • Compare results with total protein levels detected by Western blot

• Mutant OGDHL constructs:

  • Create constructs with mutations affecting enzymatic activity but preserving structure

  • Use antibodies to track localization and interactions of these mutants

  • Research has shown that OGDHL-induced DNA damage in HCC cells is independent of its enzymatic activity

• Subcellular function analysis:

  • Compare functions of mitochondrial versus nuclear OGDHL using compartment-specific markers

  • The nuclear-deficient OGDHL/3KA mutant can serve as a valuable tool for separating nuclear from mitochondrial functions

What are the technical considerations for multiplexed detection of OGDHL and its interaction partners?

Studying OGDHL in complex with its interaction partners requires sophisticated multiplexing approaches:

• Antibody compatibility:

  • Ensure primary antibodies are raised in different host species to avoid cross-reactivity

  • For co-detection of OGDHL and CDK4, select antibodies with compatible species origins

  • Consider conjugation-ready formats like Proteintech's 82981-4-PBS for custom labeling in multiplex imaging applications

• Validated antibody pairs:

  • Some manufacturers offer matched antibody pairs specifically validated for multiplex assays

  • Example: MP00023-2 includes 82981-5-PBS (capture) and 82981-4-PBS (detection) antibodies validated for cytometric bead array applications

• Signal separation strategies:

  • For fluorescence microscopy, select fluorophores with minimal spectral overlap

  • For mass cytometry applications, use metal-conjugated antibodies with distinct mass signatures

  • In multiplex ELISA, optimize antibody concentrations to minimize background and cross-reactivity

• Controls for multiplexed experiments:

  • Include single-stain controls to assess bleed-through

  • Use blocking peptides (e.g., 33R-5119) to confirm specificity in complex samples

  • Include samples with known interaction profiles as positive controls

How can OGDHL antibodies contribute to research on metabolic and neurodegenerative diseases?

OGDHL's role in energy metabolism positions it as a potential factor in metabolic and neurodegenerative disorders:

• Tissue-specific expression analysis:

  • Use OGDHL antibodies to map expression patterns in affected tissues

  • Compare expression levels between normal and disease states

  • OGDHL antibodies have been validated for detection in brain tissue, making them suitable for neurodegenerative disease research

• Post-translational modification studies:

  • Develop or select antibodies that recognize specific post-translational modifications of OGDHL

  • Investigate how these modifications change in disease states

  • Correlate modifications with alterations in localization or function

• Therapeutic target validation:

  • Use antibodies to assess the effects of experimental compounds on OGDHL expression, localization, or function

  • Monitor changes in OGDHL-dependent pathways following therapeutic interventions

  • Validate findings across multiple model systems using species-reactive antibodies

What are the best practices for validating OGDHL antibody specificity in complex experimental systems?

Thorough validation is essential for confident interpretation of OGDHL antibody results:

• Genetic controls:

  • Test antibodies in OGDHL knockout or knockdown systems

  • Observe disappearance or reduction of signal in Western blot, IHC, or other applications

  • Include reconstitution experiments with wild-type OGDHL to confirm specificity

• Peptide competition assays:

  • Pre-incubate antibody with blocking peptide (e.g., 33R-5119 for certain OGDHL antibodies)

  • Observe elimination of specific signal when the peptide blocks antibody binding

  • Include gradient concentrations of blocking peptide to assess affinity

• Multi-antibody validation:

  • Compare results using multiple antibodies targeting different epitopes of OGDHL

  • Consistent results across different antibodies increase confidence in specificity

  • Examples include antibodies targeting N-terminal regions (AA 1-110) versus internal regions

• Cross-species validation:

  • Test antibody in species with known OGDHL sequence homology

  • Confirm that reactivity matches predicted conservation of the target epitope

  • Many OGDHL antibodies show cross-reactivity with human, mouse, and rat samples, allowing for comparative studies